Pharmaceutical

Radiopharm and AtomVie partner on radioantibody development

Radiopharm Theranostics (RAD) and AtomVie have announced a partnership for the development and manufacturing of 177Lu-BetaBart.

Oct 18, 2024 - 04:00
Radiopharm and AtomVie partner on radioantibody development
Radiopharm Theranostics (RAD) and AtomVie have announced a partnership for the development and manufacturing of 177Lu-BetaBart.
Read the original article

Tags:

Previous Article

bit.bio defends European patent for ‘novel’ opti-ox technology

Next Article

Intercept’s liver disease drug Ocaliva faces FDA approval delay

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

It’s time to stop treating menopause like a disease, researchers argue in series of Lancet articles

It’s time to stop treating menopause like a disease, re...

Mar 6, 2024

CatalYm secures $150m to advance GDF-15-targeting immune modulator   

CatalYm secures $150m to advance GDF-15-targeting immun...

Jul 18, 2024

AI startup Leucine raises $7m for drug manufacturing digital twin platform

AI startup Leucine raises $7m for drug manufacturing di...

Oct 17, 2023